Session III - Basic Science - Also See: Basic Science Focus Forum

Moderator: Theodore Miclau, III, MD & Emil H. Schemitsch, MD

Fri., 10/17/08 Basic Science, Paper #16, 9:30 am OTA-2008

Procalcitonin (PCT) in Multiple Trauma Patients: Prognostic Relevance of PCT Plasma Levels and Effects of PCT Polymorphisms (CALCA) on Clinical Outcome and Posttraumatic PCT Synthesis

Frank Hildebrand, MD1 (n); Manfred Stuhrmann, MD2 (n); Matthias Kalmbach, MD2 (n);
Andrea Kaapke, MD3 (n); Michael Frink, MD1 (n); Christian Krettek, MD1 (a-AO Foundation);
1Trauma Department, Hannover Medical School, Hannover, Germany
2Institute of Human Genetics, Hannover Medical School, Hannover, Germany

Fri., 10/17/08 Basic Science, Paper #17, 9:36 am OTA-2008

•Use of the Reamer-Irrigator-Aspirator for Bone Graft Harvest: A Mechanical Comparison of Three Starting Points in Cadaveric Femurs

Ryan P. Finnan, MD (a-Dayton Area Graduated Medical Education Consortium (DAGMEC)
Grant); Michael J. Prayson, MD (a-Synthes, Canica, I-Flow and Dayton Area Graduate Medical
Education Consortium (DAGMEC) Grant; a,b-Smith + Nephew);
Tarun Goswami, DSc (n); Danielle Miller, MSb (n);
Wright State University, Department of Orthopaedic Surgery and Department of Biomedical,
Industrial and Human Factors Engineering, Dayton, Ohio, USA

Fri., 10/17/08 Basic Science, Paper #18, 9:42 am OTA-2008

Analysis of Long-Bone Fracture Nonunion by an Expression Profile of the Matrix Metalloproteinases and ADAMTS Enzyme Families

Marc R. Fajardo, MD (n); Chuanju Liu, PhD (n); Kenneth A. Egol, MD (a-Smith + Nephew,
Stryker, Synthes; a,b-Biomet; b-Exactech, Inc; d-Johnson & Johnson);
New York University-Hospital for Joint Diseases, New York, New York, USA

Fri., 10/17/08 Basic Science, Paper #19, 9:48 am OTA-2008

Δ Have We Hit the Critical Defect Trifecta? Immediate Weight Bearing, Healing and a Biodegradable Carrier in a Canine Model

Rena L. Stewart, MD1 (a-Synthes, Wyeth, OTA);
James P. Stannard, MD1 (a-Smith + Nephew, Synthes);
David A. Volgas, MD1 (a-Biomet (Interport-Cross), Smith + Nephew, Synthes, Pfizer);
Justin Duke, MD1 (n); Tien-Min Chu, PhD2 (n);
1University of Alabama at Birmingham, Birmingham, Alabama, USA;
2Indiana University, Indianapolis, Indiana, USA

Fri., 10/17/08 Basic Science, Paper #20, 10:04 am OTA-2008

2.5D Ultrasound for Measuring Leg Geometry

Peter Keppler, MD1 (n); Volker Sauer1 (n); Jean Baptiste Pinzuti2 (e-Engineer of Aesculap
Company); Josef Kozak2 (e-Engineer of Aexculap Company); Florian Gebhard, PhD1 (n);
1Department of Traumatology, University of Ulm, Ulm, Germany
2B. Braun / Aesculap AG, Tuttlingen, Germany

Fri., 10/17/08 Basic Science, Paper #21, 10:10 am OTA-2008

The Presence and Pattern of Vascular Insufficiency in the Older Patient Suffering an Unstable Ankle Fracture: The Relationship to Skin and Wound Complications

Prof. Keith Willett, FRCS1 (a-AO Research Foundation);
Robert Handley, FRCS2 (a-AO Research Foundation);
Prof. Sallie Lamb, PhD1 (a-AO Research Foundation);
Bridget Gray, RN2 (n); Ashok Handa, FRCS1 (a-AO Research Foundation);
David Coleman, FRCS2 (a-AO Research Foundation);
1University of Oxford, Oxford, United Kingdom;
2John Radcliffe Hospital, Oxford, United Kingdom

Fri., 10/17/08 Basic Science, Paper #22, 10:16 am OTA-2008

Conjunctival Contamination Is Significantly Reduced with Appropriate Eye Protection

Alfred A. Mansour, III, MD (n); Jesse L. Even, MD (n); Sharon Phillips, MSPH (n); Jennifer L. Halpern, MD (n);
Vanderbilt University Medical Center, Nashville, Tennessee, USA

Fri., 10/17/08 Basic Science, Paper #23, 10:22 am OTA-2008

What Authors Don’t Tell Us: The Quality of Reporting of Orthopaedic Randomized Trials Using a Checklist for Nonpharmacological Therapies

Simon Chan, MD (n); Mohit Bhandari, MD (n);
Division of Orthopaedic Surgery, McMaster University, Hamilton, Ontario, Canada

If noted, the author indicates something of value received. The codes are identified as a-research or institutional support; b-miscellaneous funding; c-royalties; d-stock options; e-consultant or employee; n-no conflicts disclosed, and *disclosure not available at time of printing.

• The FDA has not cleared this drug and/or medical device for the use described in this presentation   (i.e., the drug or medical device is being discussed for an “off label” use).  ◆FDA information not available at time of printing. Δ OTA Grant.